HC Wainwright Forecasts Strong Price Appreciation for Biogen (NASDAQ:BIIB) Stock

Biogen (NASDAQ:BIIB) had its target price lifted by stock analysts at HC Wainwright from $228.00 to $237.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 33.64% from the stock’s previous close.

Several other brokerages have also weighed in on BIIB. Guggenheim upped their price objective on shares of Biogen from $185.00 to $246.00 and gave the company a “buy” rating in a report on Monday, February 9th. Morgan Stanley set a $190.00 target price on Biogen in a research report on Sunday, February 8th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Biogen in a research note on Monday, February 9th. Barclays started coverage on Biogen in a report on Thursday, February 19th. They issued an “equal weight” rating and a $185.00 price target on the stock. Finally, UBS Group started coverage on Biogen in a report on Tuesday, January 6th. They set a “neutral” rating and a $185.00 price objective for the company. Twelve research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Biogen presently has an average rating of “Hold” and a consensus target price of $208.31.

Biogen Price Performance

Biogen stock opened at $177.34 on Thursday. The stock has a market capitalization of $26.03 billion, a price-to-earnings ratio of 20.13, a PEG ratio of 2.37 and a beta of 0.16. Biogen has a 52-week low of $110.04 and a 52-week high of $202.41. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. The stock’s 50 day moving average price is $186.60 and its two-hundred day moving average price is $171.35.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $1.61 by $0.38. The company had revenue of $2.28 billion during the quarter, compared to analyst estimates of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. Biogen’s revenue for the quarter was down 7.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, equities analysts predict that Biogen will post 15.83 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the transaction, the insider owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.18% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in shares of Biogen by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 17,447,092 shares of the biotechnology company’s stock valued at $3,070,514,000 after buying an additional 157,857 shares during the last quarter. State Street Corp lifted its stake in Biogen by 1.0% during the 2nd quarter. State Street Corp now owns 7,468,807 shares of the biotechnology company’s stock valued at $938,007,000 after acquiring an additional 71,897 shares in the last quarter. Geode Capital Management LLC lifted its stake in Biogen by 3.2% during the 4th quarter. Geode Capital Management LLC now owns 4,199,399 shares of the biotechnology company’s stock valued at $736,435,000 after acquiring an additional 130,618 shares in the last quarter. Norges Bank bought a new position in Biogen during the 4th quarter valued at $464,408,000. Finally, Invesco Ltd. boosted its holdings in Biogen by 4.2% during the 3rd quarter. Invesco Ltd. now owns 2,418,127 shares of the biotechnology company’s stock worth $338,731,000 after acquiring an additional 98,001 shares during the last quarter. Institutional investors own 87.93% of the company’s stock.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.